Evidence map›Paper›PMID 39552153›Full record

Trial reportESC heart failure2025

Cilostazol in patients with heart failure and preserved ejection fraction-The CLIP-HFpEF trial.

Norman Aiad, Jeanne du Fay de Lavallaz, Michael J Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S Nijjar, Julie A Lahiri, Cindy M Martin, Tamas Alexy, Markus Meyer

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05126836 (Cilostazol for HFpEF), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05126836 phase2completednot on this map

Cilostazol for HFpEF (Heart Failure With a Preserved Ejection Fraction)

TypeinterventionalSponsorUniversity of MinnesotaRan2021 to 2022Enrolled25ConditionsHeart Failure With Preserved Ejection FractionArmsCilostazol 100Mg Tab, Placebo
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Norman AiadDepartment of Medicine, Cardiology, University of Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0003-3858-7356
Jeanne du Fay de LavallazCardiovascular Research Institute Basel, Basel, Switzerland.
Michael J ZhangDepartment of Medicine, Cardiology, University of Minnesota, Minneapolis, Minnesota, USA.
Thanat ChaikijurajaiDepartment of Medicine, Cardiology, University of Minnesota, Minneapolis, Minnesota, USA.
Bo YeDepartment of Medicine, Cardiology, University of Minnesota, Minneapolis, Minnesota, USA.
Prabhjot S NijjarDepartment of Medicine, Cardiology, University of Minnesota, Minneapolis, Minnesota, USA.
Julie A LahiriDepartment of Surgery, University of Vermont Medical Center, Burlington, Vermont, USA.
Cindy M MartinDepartment of Medicine, Cardiology, University of Minnesota, Minneapolis, Minnesota, USA.
Tamas AlexyDepartment of Medicine, Cardiology, University of Minnesota, Minneapolis, Minnesota, USA.
Markus MeyerDepartment of Medicine, Cardiology, University of Minnesota, Minneapolis, Minnesota, USA.

Funding

Sarcolemmal Calcium Extrusion Defect in Patients with Diastolic DysfunctionR01HL122744 · NHLBI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI LUSTGARTEN, DANIEL L, MEYER, MARKUS · 2015 to 2019
$1.9M
Engdahl Family Chair for Heart Failure Research and in part by the National Institutes of Health R01 HL-122744University of Minnesota
6 · The paper itself

Abstract

BACKGROUND AND

aimsPatients with heart failure with preserved ejection fraction (HFpEF) tend to have low resting and exercise heart rates. Phosphodiesterase-3 (PDE-3) inhibitors improve heart rates, haemodynamics and symptoms in patients with HFpEF. Cilostazol is an oral PDE-3 inhibitor used in peripheral artery disease. This study thought to evaluate the short-term effects of cilostazol on health status, N-terminal brain natriuretic peptide (NT-proBNP) levels and mechanisms of action.

methodsThe effect of cilostazol was evaluated in 23 patients with HFpEF in a randomized placebo controlled multiple crossover trial (CLIP-HFpEF). Participants received placebo or cilostazol for 1 week followed by three crossovers to the alternate assignment at weeks 2, 3 and 4. The primary endpoint was the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) overall summary score obtained at the end of each treatment period. NT-proBNP was the secondary endpoint. In an exploratory mechanistic analysis, pulmonary artery (PA) pressures and heart rates were followed amongst the five participants with implanted pressure monitors.

resultsCilostazol improved the KCCQ score by 4.8 points (95% confidence interval, 2.0-7.7, P = 0.003). NT-proBNP levels were 448 (154-1056) pg/mL on placebo and 375 (68-974) pg/mL on cilostazol (P = 0.006). In patients with PA pressure monitors, diastolic pressure was 20.5 (18.7-23.0) mmHg on placebo and 18.0 (17.0-20.0) mmHg on cilostazol, an effect linked to higher heart rates (P < 0.001).

conclusionsAmongst patients with HFpEF, short-term treatment with cilostazol leads to improvements in health status and NT-proBNP when compared with placebo. These effects are likely conveyed by a heart rate-dependent reduction in cardiac filling pressures.

trial registrationClinicalTrials.gov Identifier: NCT05126836.

Indexed as

Heart FailureStroke VolumeVentricular Function, LeftAgedCilostazolCross-Over StudiesDouble-Blind MethodFemaleFollow-Up StudiesHeart RateHumansMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsPhosphodiesterase 3 InhibitorsCilostazolNatriuretic Peptide, BrainPeptide FragmentsPhosphodiesterase 3 Inhibitorspro-brain natriuretic peptide (1-76)diastolic functionheart failurepharmacotherapypreserved ejection fraction

Identifiers

PMID39552153
PMCPMC11911562

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.